Stelios Papadopoulos Ph.D. — Co-Founder & Chairman at Exelixis

Dr. Stelios Papadopoulos, Ph.D., is the Co-Founder of Exelixis, Inc. and has been its Chairman of the Board since January 1998. Dr. Papadopoulos is the Co-Founder of Fondation Sant??? and serves as its Chairman. He Co-founded Cellzome Inc. in 2000 and has been its Chairman since its inception. He Co-founded Cellzome AG in 2000. He Co-founded Anadys Pharmaceuticals Inc. and served as its Chairman since January 4, 2011. He is a private biotechnology investor. His career in biopharmaceuticals spans more than two decades. He served as Managing Director of Life Sciences Investment Banking division at SG Cowen Securities Corp until August 2006. In 1987, he served as the Vice President at the Equity Research Department at New Street Capital Corporation (formerly, Drexel Burnham Lambert), covering the biotechnology industry. Dr. Papadopoulos served as Managing Director of Cowen and Company, LLC and served as its Vice Chairman until August 2006. He spent six years as an investment banker with Cowen & Co., LLC, where he focused on the biotechnology and pharmaceutical sectors. Dr. Papadopoulos served as a Biotechnology Analyst at Credit Suisse (USA), Inc. (formerly, Donaldson, Lufkin & Jenrette) for two years and subsequently at Drexel Burnham Lambert, where he was elected to the Institutional Investor 1987 All-American Research Team. He was an Investment Banker at SG Cowen Securities Corp., since February 2000 and focused on the biotechnology and pharmaceutical sectors. Prior to joining the SG Cowen in February 2000, he served as an Investment Banker at UBS PaineWebber from April 1987 to February 2000. He worked at UBS Financial Services Inc. He has been the Chairman of Regulus Therapeutics Inc. since June 11, 2013. He has been the Chairman of the Board of Biogen Inc. since June 12, 2014 and has been its Independent Director since July 2008. He served as the Chairman of PaineWebber Development Corporation from June 1998 to February 2000. He served as a Vice Chairman of BG Medicine, Inc. since April 2007 and has been its Director since 2003. Dr. Papadopoulos served as the Chairman and Member of Advisory Board at SG Americas Securities, LLC. He served as the Vice Chairman of SG Americas Securities, LLC. He has been a Member of the Supervisory Board/member of the Board of Directors of Cellzome Inc. since 2000. He serves as a Director of Cellzome AG. He has been Independent Director of Exelixis, Inc. since December 1994 and Regulus Therapeutics Inc. since January 2009. He serves as a Director of Joule Unlimited, Inc. (formerly, Joule Biotechnologies). He serves as a Member of the Advisory Board at BioLab.org. He serves as a Member of Strategic Advisory Board at Symphony Capital LLC. Dr. Papadopoulos is a Member of the Board of Visitors of Duke University Medical Center and a Member of the Board of Directors of the National Marrow Donor Program. He has been a Director at BG Medicine, Inc since 2003. He served as a Member of the Board of Directors of Neuronyx, Inc. He served as Independent Director of Regulus Therapeutics, LLC since July 2008. He served as a Director of Anadys Pharmaceuticals Inc. from May 2000 to January 31, 2011. He served as a Director of GenVec, Inc., from August 2003 to October 2006, SGX Pharmaceuticals, Inc. from July 2001 to September 28, 2006 and Diacrin, Inc. from 1991 to August 2003. Before coming to Wall Street in 1985, he was on the faculty of the Department of Cell Biology at New York University Medical Center. Dr. Papadopoulos is affiliated with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. He holds a Ph.D. in Biophysics and an M.B.A. in Finance, both from New York University.